Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis
Björn Carlsson, Daniel Lindén, Gabriella Brolén, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 12, pp. 1305-1320
Open Access | Times Cited: 141

Showing 1-25 of 141 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1856
Liver cirrhosis
Pere Ginés, Aleksander Krag, Juan G. Abraldeṣ, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1359-1376
Closed Access | Times Cited: 978
Challenges and opportunities in NASH drug development
Stephen A. Harrison, Alina M. Allen, Julie Dubourg, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 562-573
Closed Access | Times Cited: 199
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 165
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Agnieszka Karkucińska‐Więckowska, Inês C. M. Simões, Piotr Kalinowski, et al.
European Journal of Clinical Investigation (2021) Vol. 52, Iss. 3
Open Access | Times Cited: 105
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 83
Clinical Trial Landscape in NASH
Stephen A. Harrison, Rohit Loomba, Julie Dubourg, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2001-2014
Closed Access | Times Cited: 75
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study
Quentin M. Anstee, Brent A. Neuschwander‐Tetri, Vincent Wai‐Sun Wong, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 1, pp. 124-134.e1
Open Access | Times Cited: 73
Therapeutic opportunities for the treatment of NASH with genetically validated targets
Daniel Lindén, Stefano Romeo
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 1056-1064
Closed Access | Times Cited: 46
Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries
Ehsan Amini‐Salehi, Negin Letafatkar, Naeim Norouzi, et al.
Archives of Medical Research (2024) Vol. 55, Iss. 6, pp. 103043-103043
Closed Access | Times Cited: 37
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials
Javier Armisen, Mitra Rauschecker, Janeli Sarv, et al.
Journal of Hepatology (2025)
Closed Access | Times Cited: 4
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Agostino Di Ciaula, Salvatore Passarella, Harshitha Shanmugam, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5375-5375
Open Access | Times Cited: 94
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne, Giovanni Targher
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 28-43
Open Access | Times Cited: 79
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy (2021) Vol. 38, Iss. 5, pp. 2130-2158
Open Access | Times Cited: 67
Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study
Hideki Fujii, Michihiro Iwaki, Hideki Hayashi, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 2, pp. 370-379
Closed Access | Times Cited: 63
The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans
Panu K. Luukkonen, Kimmo Porthan, Noora Ahlholm, et al.
Cell Metabolism (2023) Vol. 35, Iss. 11, pp. 1887-1896.e5
Open Access | Times Cited: 41
Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019
Phillipp Hartmann, Xinlian Zhang, Rohit Loomba, et al.
Hepatology (2023) Vol. 78, Iss. 4, pp. 1168-1181
Open Access | Times Cited: 39
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
Takanori Ito, Mindie H. Nguyen
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 413-428
Open Access | Times Cited: 35
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 31
Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
Seyedeh Kosar Mahmoudi, Shadi Tarzemani, Taha Aghajanzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 14
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 225-234
Open Access | Times Cited: 12
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease
Naga Chalasani, Eduardo Vilar‐Gómez, Rohit Loomba, et al.
Hepatology (2024) Vol. 80, Iss. 5, pp. 1212-1226
Closed Access | Times Cited: 12
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
Fernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, et al.
JHEP Reports (2024) Vol. 6, Iss. 7, pp. 101092-101092
Open Access | Times Cited: 9
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success
Joost P.H. Drenth, Jörn M. Schattenberg
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 12, pp. 1365-1375
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top